T cell receptor sequences diagnostic for COVID-19 and related compositions
US12266425B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2021 |
| Grant date | Apr 1, 2025 |
| Priority date | — |
| Expiry date | Jul 1, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/57
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods of assessing a biological sample obtained from an individual for the presence of a T cell that expresses a T cell receptor (TCR) comprising a TCRβ CDR3 sequence set forth in Table 1. Such methods further comprise identifying the individual as having COVID-19 when the presence of the TCR is detected. The presence of one or more of these TCRs may be of use in prognosticating severity of COVID-19 in the individual and the individual may be treated based on the expected severity of COVID-19. Treatment methods may include administering to the individual a T cell engineered to express the TCR. Such engineered T cells are also disclosed. Also provided are compositions and multimers that find use, e.g., in practicing the methods of the present disclosure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.